Overview Dividends

(SYRE) Spyre Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00773J2024

Monoclonal Antibodies

Biotechnology
Market Cap in USD: 2,224m
IPO / Inception: 2016-04-07
Return 12m vs S&P 500: 3.02%

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 92.9%
Value at Risk 5%th 145%
Relative Tail Risk -5.30%
Reward TTM
Sharpe Ratio 0.51
Alpha -9.12
CAGR/Max DD 0.53
Character TTM
Hurst Exponent 0.509
Beta 1.702
Beta Downside 2.001
Drawdowns 3y
Max DD 82.62%
Mean DD 39.41%
Median DD 38.55%

Description: SYRE Spyre Therapeutics November 16, 2025

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotech focused on inflammatory bowel disease (IBD). Its lead asset, SPY001, is a human IgG1 monoclonal antibody that selectively targets the α4β7 integrin, a mechanism shared with the approved drug vedolizumab. In pre-clinical development the company is combining SPY001 with SPY002 (anti-TL1A) as SPY120, and is pursuing additional programs targeting IL-23 (SPY003) and various dual-antibody combos (SPY130, SPY230).

Assuming the most recent Form 10-Q (Q2 2024) is accurate, Spyre reported cash and cash equivalents of roughly $45 million, giving it an estimated runway of 12–15 months at its current burn rate of about $15 million per quarter. The global IBD biologics market is projected to reach ~$14 billion by 2028 (≈7 % CAGR), driven by rising prevalence and a shift toward targeted therapies, which creates a sizable addressable market for novel integrin or TL1A inhibitors. Recent sector trends show a tightening of capital for early-stage biotech, making cash efficiency and clear differentiation from existing agents critical success factors.

For a deeper quantitative assessment of Spyre’s valuation and risk profile, you may find it useful to explore the company’s metrics on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-149.0m TTM) > 0 and > 6% of Revenue (6% = 53.2k TTM)
FCFTA -0.32 (>2.0%) and ΔFCFTA 3.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 51.7k% (prev 34.9k%; Δ 16.8kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.32 (>3.0%) and CFO -161.9m <= Net Income -149.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 10.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (60.4m) change vs 12m ago 18.72% (target <= -2.0% for YES)
Gross Margin -5007 % (prev 7.49%; Δ -5014 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.19% (prev 0.25%; Δ -0.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.64 (EBITDA TTM -177.9m / Interest Expense TTM 21.3m) >= 6 (WARN >= 3)

Altman Z'' -24.31

(A) 0.91 = (Total Current Assets 504.6m - Total Current Liabilities 46.3m) / Total Assets 504.6m
(B) -2.11 = Retained Earnings (Balance) -1.07b / Total Assets 504.6m
warn (B) unusual magnitude: -2.11 — check mapping/units
(C) -0.12 = EBIT TTM -56.3m / Avg Total Assets 462.8m
(D) -21.50 = Book Value of Equity -1.06b / Total Liabilities 49.5m
Total Rating: -24.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.10

1. Piotroski 0.0pt
2. FCF Yield -8.88%
3. FCF Margin data missing
4. Debt/Equity 0.19
5. Debt/Ebitda 0.36
6. ROIC - WACC (= -30.25)%
7. RoE -31.18%
8. Rev. Trend -68.72%
9. EPS Trend 76.29%

What is the price of SYRE shares?

As of December 04, 2025, the stock is trading at USD 32.20 with a total of 1,313,203 shares traded.
Over the past week, the price has changed by +8.24%, over one month by +35.41%, over three months by +91.55% and over the past year by +18.08%.

Is SYRE a buy, sell or hold?

Spyre Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy SYRE.
  • Strong Buy: 10
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SYRE price?

Issuer Target Up/Down from current
Wallstreet Target Price 53.6 66.4%
Analysts Target Price 53.6 66.4%
ValueRay Target Price 30.9 -4.2%

SYRE Fundamental Data Overview December 02, 2025

Market Cap USD = 2.22b (2.22b USD * 1.0 USD.USD)
P/S = 650.2181
P/B = 7.7779
Beta = 3.169
Revenue TTM = 886.0k USD
EBIT TTM = -56.3m USD
EBITDA TTM = -177.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 84.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -64.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.82b USD (2.22b + Debt 84.6m - CCE 486.2m)
Interest Coverage Ratio = -2.64 (Ebit TTM -56.3m / Interest Expense TTM 21.3m)
FCF Yield = -8.88% (FCF TTM -161.9m / Enterprise Value 1.82b)
FCF Margin = -18.3k% (FCF TTM -161.9m / Revenue TTM 886.0k)
Net Margin = -16.8k% (Net Income TTM -149.0m / Revenue TTM 886.0k)
Gross Margin = -5007 % ((Revenue TTM 886.0k - Cost of Revenue TTM 45.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.61 (Enterprise Value 1.82b / Total Assets 504.6m)
Interest Expense / Debt = 25.20% (Interest Expense 21.3m / Debt 84.6m)
Taxrate = -0.0% (0.0 / -11.2m)
NOPAT = -56.3m (EBIT -56.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 10.90 (Total Current Assets 504.6m / Total Current Liabilities 46.3m)
Debt / Equity = 0.19 (Debt 84.6m / totalStockholderEquity, last quarter 455.1m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -64.9m / EBITDA -177.9m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -64.9m / FCF TTM -161.9m)
Total Stockholder Equity = 477.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.52% (Net Income -149.0m / Total Assets 504.6m)
RoE = -31.18% (Net Income TTM -149.0m / Total Stockholder Equity 477.8m)
RoCE = -12.28% (EBIT -56.3m / Capital Employed (Total Assets 504.6m - Current Liab 46.3m))
RoIC = -17.48% (negative operating profit) (NOPAT -56.3m / Invested Capital 322.0m)
WACC = 12.76% (E(2.22b)/V(2.31b) * Re(12.29%) + D(84.6m)/V(2.31b) * Rd(25.20%) * (1-Tc(-0.0)))
Discount Rate = 12.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 66.84%
Fair Price DCF = unknown (Cash Flow -161.9m)
EPS Correlation: 76.29 | EPS CAGR: 3.89% | SUE: 0.20 | # QB: 0
Revenue Correlation: -68.72 | Revenue CAGR: -80.21% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.66 | Chg30d=+0.071 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.72 | Chg30d=+0.404 | Revisions Net=+1 | Growth EPS=-28.5% | Growth Revenue=+0.0%

Additional Sources for SYRE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle